CClinicalTrials.gg
Sign In
CompletedNCT01854944Updated Feb 4, 2016Results posted

PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia

A Phase 1 interventional study of Brexpiprazole 1mg to 4mg in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2016-02-04.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to determine how low and high does of brexpiprazole binds to certain receptors in the brain. This will be determined by PET scans taken pre-dose and post-dose.

02

Conditions studied

  • Schizophrenia

Browse trials for

03

In context

Schizophrenia

3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.

This study's enrollment of 12 is below the median of 70 across 2,872 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 289 studies on the registry; 18 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 69 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • A diagnosis of Schizophrenia.
  • Ability to provide written informed consent.
  • Ability to understand the protocol and meet the protocol requirements.
  • Must be in good physical health determined by ECG and laboratory values, medical history and physical examinations.
  • Has stable disease, defined as meeting all of the following criteria: A CGI-S score \<= 4 (moderately ill); A PANSS total score \<= 60; A score of \<= 4 (moderate) on any of the following PANSS items: (P7 (hostility); G8 (uncooperativeness)).
  • Body mass index of 19 to 35 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Sexually active males and females of childbearing potential who are not practicing double-barrier birth control, or who will not remain abstinent, during the trial and for 30 days following the last dose of trial medication. If employing birth control, 2 of the following precautions must be used: vasectomy, partner who uses hormonal contraception, tubal ligation, vaginal diaphragm, nonhormonal intrauterine device, condom, or sponge with spermicide.
  • Females who are pregnant or lactating. A negative serum pregnancy test must be confirmed prior to the first dose of trial medication for all female subjects.
  • Subjects presenting with a first episode of schizophrenia based on the clinical judgment of the investigator.
  • Subjects who have received continuous medication therapy to treat schizophrenia for less than 6 months prior to the drug-free interval.
  • Subjects with schizophrenia who are considered resistant/refractory to antipsychotic treatment by history, who have a history of failure to clozapine, or who are responsive only to clozapine treatment.
  • Subjects with a current DSM-IV-TR Axis I diagnosis other than schizophrenia including MDD, bipolar disorder, delirium, dementia, amnestic, or other cognitive disorders or subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  • Subjects who, in the opinion of the investigator, cannot be rated reliably on the battery of movement rating scales required by the protocol.
  • Subjects with a significant risk of violent behavior, a significant risk of committing suicide based on history or investigator's judgment, or who have attempted suicide within 2 years of cohort assignment.
  • Subjects with clinically significant tardive dyskinesia at enrollment.
  • Subjects who experience clinical deterioration during the drug-free interval, such that they require prohibited rescue therapy, will not meet the trial criteria and will be replaced.
  • Subjects who experienced an acute exacerbation requiring hospitalization within 3 months prior to the Screening Visit or between the Screening and Baseline Visits.
  • Subjects who experienced an acute exacerbation requiring change in antipsychotic medication (with reference to drug or dose) within the last 4 weeks prior to baseline.
  • Subjects who have a history of myocardial infarction, hypertension, or diabetes or who have evidence of other medical conditions that would expose them to an undue risk of a significant AE or interfere with assessments of safety or efficacy during the course of the trial, including, but not limited to, hepatic, renal, respiratory, cardiovascular, endocrine, neurologic, hematologic, or immunologic disease. The medical monitor must be contacted to discuss any such condition prior to cohort assignment.
  • Subjects who have any of the following neurologic diagnoses, whether under treatment or not, whether stable or not: migraine, epilepsy, Parkinson's disease, Alzheimer's disease, multiple sclerosis, residual of stroke, transient cerebral ischemic attacks, cerebral palsy, or any condition that requires intermittent or maintenance treatment or which is manifested by any abnormality on neurologic examination. A subject with tardive dyskinesia or other nonclinically significant symptoms of EPS due solely to the current or prior use of antipsychotic medications is not excluded by this criterion. Single-nerve peripheral palsies are also not excluded by this criterion: eg, Bell's palsy or radial-nerve palsy or fixed residuals from traumatic injury.

History of or current hepatitis or acquired immunodeficiency syndrome or carriers of HBsAg and/or anti-HCV or HIV antibodies.

  • Subjects with a history of thyroid pathology (unless the condition has been stabilized with medications for at least the past 3 months) and/or abnormal thyroid laboratory results.
  • Subjects with a history of neuroleptic malignant syndrome.
  • Subjects with a history of seizure disorder.
  • Subjects who meet DSM-IV-TR criteria for substance dependence within 6 months prior to cohort assignment (excluding caffeine and nicotine), including alcohol and benzodiazepines, and/or a positive alcohol (breath or urine) test or a positive urine screen for drugs of abuse. (In the case where a subject had a positive screen for stimulants and/or marijuana and was therefore excluded, the medical monitor should be contacted to determine if rescreening is an option.)
  • Subjects who had any major surgery, any blood transfusion, or donated blood or plasma within 30 days prior to enrollment.

  • The following laboratory test, vital sign, and ECG results are exclusionary:

    1. Platelets \<= 75,000/mm3
    2. Hemoglobin \<= 9 g/dL
    3. Neutrophils, absolute \<= 1000/mm3
    4. AST > 2 times upper limit of normal
    5. ALT > 2 times upper limit of normal
    6. Creatinine >= 2 mg/dL
  • Subjects with electrolytes outside of the normal range will not be enrolled in the trial without prior review and approval from the medical monitor.
  • Subjects who have sitting (performed first) or supine blood pressure, after resting for >= 3 minutes, higher than 140/90 mmHg or lower than 100/50 mmHg. Upon standing from the supine position, subjects who have a fall in systolic blood pressure >= 20 mmHg or a fall in diastolic blood pressure >= 10 mm Hg after 1 to 3 minutes in the standing position. (Any repeated out-of-range values not deemed clinically significant need to be discussed with the medical monitor to determine eligibility.)
  • Subjects who have a supine pulse rate, after resting for >= 3 minutes, outside the range of 40 to 90 bpm.
  • Subjects with any ECG abnormality at Screening, prior to dosing, will be excluded, including but not limited to, a PR interval > 220 msec, QRS interval > 110 msec, QTc > 450 msec, QTcF > 450 msec, QTcB > 450 msec or the increase in QTcB is considered significant by the investigator, abnormal U waves, or other minor ST-T wave changes which are considered clinically significant.
  • Prohibited concomitant medications/therapies used for the following time period prior to Day -1 and for the duration of the trial include:

  • Antipsychotics

    1. Use of oral antipsychotics within 21 days prior to Day -1;
    2. Use of long-acting injectable antipsychotics within 6 months.

  • Anxiolytics and Sleep Aids

    1. Regular use of benzodiazepines for 2 weeks (lorazepam [\<= 6 mg daily up to 48 hours prior to PK and PD assessments] can be used as rescue therapy during the 21 days prior to Day -1 and [\<= 4 mg daily up to 48 hours prior to PK and PD assessments or up to 24 hours prior to the completion of the EPS rating scales or C-SSRS] during the treatment period).

  • Mood Stabilizers

    1. Use of lamotrigine within 14 days.

  • Selective Serotonin Reuptake Inhibitors

    1. Use of Prozac within 28 days;
    2. Use of Paxil within 14 days;
    3. Use of Zoloft, Luvox, or Celexa within 7 days.

  • Serotonin and Norepinephrine Reuptake Inhibitors

    1. Use of Effexor within 3 days;
    2. Use of duloxetine within 14 days.

  • Other

    1. Use of Symbyax within 28 days;
    2. Use of CYP2D6 or CYP3A4 inhibitors or CYP3A4 inducers within 14 days;
    3. Use of electroconvulsive therapy within 2 months.
  • Use and discontinuation of any other therapy (prescription medication, over-the counter, herbal medication, or vitamins) not listed above must be approved by the sponsor and the medical monitor.
  • Subjects who received brexpiprazole in a prior clinical trial.
  • Subjects who received any investigational agent in a clinical trial within 90 days prior to Screening.
  • Consumption of alcohol and/or food and beverages containing methylxanthines, grapefruit, grapefruit juice, Seville oranges, or Seville orange juice within 72 hours prior to dosing and for the duration of the trial.
  • Subjects who are heavy smokers (ie, > 21 cigarettes per day). Other
  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (eg, infectious disease) illness must not be enrolled into this trial.
  • Subjects with a history of allergy to more than one class of medications.
  • Any subject who, in the opinion of the investigator, should not participate in the trial.
  • A history of difficulty in donating blood.
  • Exposure to any substances known to stimulate hepatic microsomal enzymes within 30 days prior to Screening through the end of the trial (eg, occupational exposure to pesticides, organic solvents).

  • Additionally, subjects who meet the following imaging exclusion criteria will not be included in this trial:

    1. Subjects who suffer from claustrophobia.
    2. Subjects with MRI-incompatible implants and other contraindications for MRI, such as pacemaker, artificial joints, nonremovable body piercings, tattoos larger than 1 cm in diameter, metal fragments, claustrophobia, etc.
    3. Subjects who have received a diagnostic or therapeutic radiopharmaceutical within 7 days prior to participation in this trial.
    4. Participation in other research trials involving ionizing radiation within 1 year of the PET scans that would cause the subject to exceed the yearly dose limits for normal subjects.
    5. Subjects with history of IV drug use which would prevent venous access for PET tracer injection.
    6. Severe motor problems that prevent the subject from lying still for PET and MRI.
    7. Subjects who complain of chronic pain (eg, as the result of rheumatoid arthritis).
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Brexpiprazole 1mg to 4mg

    Three cohorts of subjects will be evaluated: - Cohorts 1 and 3 will receive high doses of brexpiprazole, and Cohort 2 will receive low doses of brexpiprazole.

    Drug: Brexpiprazole 1mg to 4mg

Interventions

  • DrugBrexpiprazole 1mg to 4mg

    Also known as: Brexpiprazole

06

What researchers measure

Primary outcomes

  1. Change in Percentage Dopamine D2/D3 Receptor Occupancy

    Dopamine receptor occupancy measured using the radiotracer \[11C\]-(+)-PHNO in low and high dose. The binding of brexpiprazole to the D2/D3 receptors were assessed by comparing the binding potential from the Baseline scan (prior to treatment) to that of Day 10 (after treatment). The D2/D3 receptors following administration of a 1- and 4-mg doses of brexpiprazole were assessed and the occupancy estimates were averaged across brain regions 4 hours post-last dose on Day 10.

    Time frame: Baseline to 4 hours post-last dose on Day 10

  2. Change in Percentage 5-HT1A Receptor Occupancy

    Mean (±SD) Serotonin 5-HT1A Receptor Occupancy Using the Radiotracer \[11C\]CUMI101 in high dose only. In cohorts 1, 2 and 3, the binding of brexpiprazole to the 5-HT1A receptors was assessed by comparing the binding potential from the Baseline scan (prior to treatment) to that of Day 10 (after treatment). The 5-HT1A receptors following administration of a 4-mg dose of brexpiprazole was assessed and the occupancy estimates were averaged across brain regions 4 hours post-last dose on Day 10.

    Time frame: Baseline to 4 hours post-last dose on Day 10

  3. Change in Percentage 5-HT2A Receptor Occupancy

    Mean (±SD) Serotonin 5-HT2A Receptor Occupancy Using the Radiotracer \[11C\]MDL100907 (in low and high dose). The 5-HT2A receptors following administration of 1- and 4-mg doses of brexpiprazole were assessed and the occupancy estimates were averaged across brain regions 4 hours post-last dose on Day 10.

    Time frame: Baseline and 4 hours post-last dose on Day 10

  4. Change in Occupancy at Serotonin Transporter (SERT)

    Mean (±SD) SERT Occupancy Using the Radiotracer \[11C\]DASB in high dose only. Occupancy estimates were averaged across brain regions 4 hours post-last dose.

    Time frame: Baseline to 4 hours post-last dose on Day 10

Secondary outcomes

  1. Area Under the Concentration-time Curve (AUCτ) During a Dosing Interval at Steady-state for Brexpiprazole and Its Metabolite DM-3411

    AUC during a dosing interval at steady-state for brexpiprazole and its metabolite DM-3411. Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.

    Time frame: Baseline to Day 10

  2. Peak (Maximal) Concentration of Drug in Plasma (Cmax) for Brexpiprazole and Its Metabolite DM-3411

    (Cmax) Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.

    Time frame: Baseline to Day 10

  3. Apparent Clearance of Drug From Plasma After Extravascular Administration (CL/F; Only Brexpiprazole)

    PK parameter - CL/F was assessed for brexpiprazole only. Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.

    Time frame: Baseline to Day 10

  4. Time to Maximum (Peak) Plasma Concentration (Tmax) for Brexpiprazole and Its Metabolite DM-3411

    Tmax for brexpiprazole and its metabolite DM-3411. Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.

    Time frame: Baseline to Day 10

  5. Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score

    The AIMS Scale was an extrapyramidal symptoms (EPS) rating scale. The AIMS is a 12 item scale. The first 10 items e.g. facial and oral movements (items 1-4), extremity movements (items 5 and 6), trunk movements (item 7), investigators global assessment of dyskinesia (items 8 to 10). The first 10 items are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28, with a higher score indicating worse outcome. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.

    Time frame: Baseline to Day 6, 11 and Last Visit

  6. Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score

    The SAS is a rating scale used to measure EPS. The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40, with higher scores indicating worse outcome. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.

    Time frame: Baseline to Day 6, 11 and Last Visit

  7. Mean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score

    The BARS consisted of 4 items related to akathisia: objective observation of akathisia by the study physician, subjective feelings of restlessness by the participant, participant distress due to akathisia, and global evaluation of akathisia. The first 3 items were rated on a 4-point scale, with a score of 0 = absence of symptoms and a score of 3 = severe condition. The global clinical evaluation were made on a 6-point scale, (0=absent, 1=questionable, 2=mild, 3=moderate, 4=marked, 5=severe). To complete this scale, participants were observed while they were seated and then stood for a minimum of 2 minutes in each position. Symptoms observed in other situations (e.g., while engaged in neutral conversation or engaged in activity on the ward) may also be rated. Subjective phenomena were to be elicited by direct questioning. The BARS total score (when combined) ranged from 0 to 18, with higher values indicating a severe condition.

    Time frame: Baseline to Day 6, 11 and Last Visit

  8. Percentage of Participants Who Reported at Least One Occurrence of Suicidality, Suicidal Behavior and Suicidal Ideation on the Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). The suicidal ideation intensity total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) which leads to the range of the total score from 0 to 25, with a higher score indicating a worse outcome. A missing score of any item resulted in a missing total score. If no suicidal ideation was reported, a score of 0 was given to the intensity scale. Last Visit is last scheduled post-baseline evaluation including early termination evaluation.

    Time frame: Baseline to Last Visit

  9. Mean Change From Baseline in Positive and Negative Symptom Scale (PANSS) Total Score

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome). Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.

    Time frame: Baseline to Day 6, 11 and Last Visit

  10. Mean Change From Baseline in PANNS Positive Subscale Score

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.

    Time frame: Baseline to Day 6, 11 and Last Visit

  11. Mean Change From Baseline in PANSS Negative Subscale Score

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.

    Time frame: Baseline to Day 6, 11 and Last Visit

  12. Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score

    The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.

    Time frame: Baseline to Day 6, 11 and Last Visit

  13. Mean Change From Baseline in Clinical Global Impression-Improvement (CGI-I) Score

    The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.

    Time frame: Baseline to Day 6, 11 and Last Visit

07

Results

Posted Feb 4, 2016

Participant flow

A Phase 1, single center, open-label trial of up to 12 enrolled participants.

Participant flow — Overall Study
MilestoneCohort 1 - Brexpiprazole 4 mgCohort 2 - Brexpiprazole 1 mgCohort 3 - Brexpiprazole 4 mg
Started444
Completed443
Not completed001
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryChange in Percentage Dopamine D2/D3 Receptor Occupancy

Dopamine receptor occupancy measured using the radiotracer \[11C\]-(+)-PHNO in low and high dose. The binding of brexpiprazole to the D2/D3 receptors were assessed by comparing the binding potential from the Baseline scan (prior to treatment) to that of Day 10 (after treatment). The D2/D3 receptors following administration of a 1- and 4-mg doses of brexpiprazole were assessed and the occupancy estimates were averaged across brain regions 4 hours post-last dose on Day 10.

Time frame:
Baseline to 4 hours post-last dose on Day 10
Reported as:
Mean · percentage occupancy
Change in Percentage Dopamine D2/D3 Receptor Occupancy
percentage occupancyBrexpiprazole 1mgBrexpiprazole 4 mg
6-region model (D2 receptor)36 ± 1659 ± 5
6-region model (D3 receptor)2 ± 313 ± 10
8-region model (D2 receptor)27 ± 2567 ± 15
8-region model (D3 receptor)1 ± 231 ± 8
PrimaryChange in Percentage 5-HT1A Receptor Occupancy

Mean (±SD) Serotonin 5-HT1A Receptor Occupancy Using the Radiotracer \[11C\]CUMI101 in high dose only. In cohorts 1, 2 and 3, the binding of brexpiprazole to the 5-HT1A receptors was assessed by comparing the binding potential from the Baseline scan (prior to treatment) to that of Day 10 (after treatment). The 5-HT1A receptors following administration of a 4-mg dose of brexpiprazole was assessed and the occupancy estimates were averaged across brain regions 4 hours post-last dose on Day 10.

Time frame:
Baseline to 4 hours post-last dose on Day 10
Reported as:
Mean · percentage occupancy
Change in Percentage 5-HT1A Receptor Occupancy
percentage occupancyBrexpiprazole 4mg
Change in Percentage 5-HT1A Receptor Occupancy4 ± 6
PrimaryChange in Percentage 5-HT2A Receptor Occupancy

Mean (±SD) Serotonin 5-HT2A Receptor Occupancy Using the Radiotracer \[11C\]MDL100907 (in low and high dose). The 5-HT2A receptors following administration of 1- and 4-mg doses of brexpiprazole were assessed and the occupancy estimates were averaged across brain regions 4 hours post-last dose on Day 10.

Time frame:
Baseline and 4 hours post-last dose on Day 10
Reported as:
Mean · percentage occupancy
Change in Percentage 5-HT2A Receptor Occupancy
percentage occupancyBrexpiprazole 1mgBrexpiprazole 4 mg
Change in Percentage 5-HT2A Receptor Occupancy28 ± 1045 ± 7
PrimaryChange in Occupancy at Serotonin Transporter (SERT)

Mean (±SD) SERT Occupancy Using the Radiotracer \[11C\]DASB in high dose only. Occupancy estimates were averaged across brain regions 4 hours post-last dose.

Time frame:
Baseline to 4 hours post-last dose on Day 10
Reported as:
Mean · percentage occupancy
Change in Occupancy at Serotonin Transporter (SERT)
percentage occupancyBrexpiprazole 4mg
Change in Occupancy at Serotonin Transporter (SERT)-3 ± 15
SecondaryArea Under the Concentration-time Curve (AUCτ) During a Dosing Interval at Steady-state for Brexpiprazole and Its Metabolite DM-3411

AUC during a dosing interval at steady-state for brexpiprazole and its metabolite DM-3411. Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.

Time frame:
Baseline to Day 10
Reported as:
Mean · hr*ng/mL
Area Under the Concentration-time Curve (AUCτ) During a Dosing Interval at Steady-state for Brexpiprazole and Its Metabolite DM-3411
hr*ng/mLCohort 1 - Brexpiprazole 4mgCohort 2 - Brexpiprazole 1mgCohort 3 - Brexpiprazole 4 mg
Brexpiprazole2520 ± 1290716 ± 1181410 ± 352
DM-3411807 ± 205329 ± 227761 ± 397
SecondaryPeak (Maximal) Concentration of Drug in Plasma (Cmax) for Brexpiprazole and Its Metabolite DM-3411

(Cmax) Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.

Time frame:
Baseline to Day 10
Reported as:
Mean · ng/mL
Peak (Maximal) Concentration of Drug in Plasma (Cmax) for Brexpiprazole and Its Metabolite DM-3411
ng/mLCohort 1 - Brexpiprazole 4mgCohort 2- Brexpiprazole 1mgCohort 3 - Brexpiprazole 4mg
Brexpiprazole126 ± 58.346.5 ± 7.4770.9 ± 18.8
DM-341137.1 ± 10.817.3 ± 10.435.7 ± 18.6
SecondaryApparent Clearance of Drug From Plasma After Extravascular Administration (CL/F; Only Brexpiprazole)

PK parameter - CL/F was assessed for brexpiprazole only. Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.

Time frame:
Baseline to Day 10
Reported as:
Mean · mL/hr
Apparent Clearance of Drug From Plasma After Extravascular Administration (CL/F; Only Brexpiprazole)
mL/hrCohort 1 - Brexpiprazole 4 mgCohort 2 - Brexpiprazole 1mgCohort 3 - Brexpiprazole 4mg
Apparent Clearance of Drug From Plasma After Extravascular Administration (CL/F; Only Brexpiprazole)1960 ± 9601420 ± 2422970 ± 831
SecondaryTime to Maximum (Peak) Plasma Concentration (Tmax) for Brexpiprazole and Its Metabolite DM-3411

Tmax for brexpiprazole and its metabolite DM-3411. Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.

Time frame:
Baseline to Day 10
Reported as:
Median · hour
Time to Maximum (Peak) Plasma Concentration (Tmax) for Brexpiprazole and Its Metabolite DM-3411
hourCohort 1 - Brexpiprazole 4mgCohort 2 - Brexpiprazole 1mgCohort 3 - Brexpiprazole 4mg
Brexpiprazole1.92 (0.00 to 2.92)1.50 (0.93 to 1.93)4.87 (3.10 to 6.00)
DM-34112.42 (0.00 to 24.08)1.51 (0.00 to 11.92)11.87 (3.10 to 24.00)
SecondaryMean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score

The AIMS Scale was an extrapyramidal symptoms (EPS) rating scale. The AIMS is a 12 item scale. The first 10 items e.g. facial and oral movements (items 1-4), extremity movements (items 5 and 6), trunk movements (item 7), investigators global assessment of dyskinesia (items 8 to 10). The first 10 items are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28, with a higher score indicating worse outcome. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.

Time frame:
Baseline to Day 6, 11 and Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score
Units on a scaleCohort 1 - Brexpiprazole 4mgCohort 2 - Brexpiprazole 1mgCohort 3 Brexpiprazole 4mg
Day 60 ± 00 ± 00.3 ± 0.5
Day 110 ± 00 ± 00 ± 0
Last Visit0 ± 00 ± 00 ± 0
SecondaryMean Change From Baseline in Simpson-Angus Scale (SAS) Total Score

The SAS is a rating scale used to measure EPS. The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40, with higher scores indicating worse outcome. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.

Time frame:
Baseline to Day 6, 11 and Last Visit
Reported as:
Mean · Units on scale
Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score
Units on scaleCohort 1 - Brexpiprazole 4mgCohort 2- Brexpiprazole 1mgCohort 3 Brexpiprazole 4mg
Day 60.3 ± 0.50 ± 0-0.3 ± 1.3
Day 110 ± 00 ± 0-0.7 ± 1.2
Last Visit0 ± 00 ± 0-0.5 ± 1.0
SecondaryMean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score

The BARS consisted of 4 items related to akathisia: objective observation of akathisia by the study physician, subjective feelings of restlessness by the participant, participant distress due to akathisia, and global evaluation of akathisia. The first 3 items were rated on a 4-point scale, with a score of 0 = absence of symptoms and a score of 3 = severe condition. The global clinical evaluation were made on a 6-point scale, (0=absent, 1=questionable, 2=mild, 3=moderate, 4=marked, 5=severe). To complete this scale, participants were observed while they were seated and then stood for a minimum of 2 minutes in each position. Symptoms observed in other situations (e.g., while engaged in neutral conversation or engaged in activity on the ward) may also be rated. Subjective phenomena were to be elicited by direct questioning. The BARS total score (when combined) ranged from 0 to 18, with higher values indicating a severe condition.

Time frame:
Baseline to Day 6, 11 and Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score
Units on a scaleCohort 1 - Brexpiprazole 4mgCohort 2- Brexpiprazole 1mgCohort 3 Brexpiprazole 4mg
Day 60.5 ± 1.00 ± 00.5 ± 1.0
Day 110.5 ± 1.00 ± 00.0 ± 0.0
Last Visit0.5 ± 1.00 ± 00.0 ± 0.0
SecondaryPercentage of Participants Who Reported at Least One Occurrence of Suicidality, Suicidal Behavior and Suicidal Ideation on the Columbia-Suicide Severity Rating Scale (C-SSRS)

The C-SSRS captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). The suicidal ideation intensity total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) which leads to the range of the total score from 0 to 25, with a higher score indicating a worse outcome. A missing score of any item resulted in a missing total score. If no suicidal ideation was reported, a score of 0 was given to the intensity scale. Last Visit is last scheduled post-baseline evaluation including early termination evaluation.

Time frame:
Baseline to Last Visit
Reported as:
Number · Percentage of participants
Percentage of Participants Who Reported at Least One Occurrence of Suicidality, Suicidal Behavior and Suicidal Ideation on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Percentage of participantsCohort 1 - Brexpiprazole 4mgCohort 2- Brexpiprazole 1mgCohort 3 Brexpiprazole 4mg
Suicidality000
Suicidal behaviour000
Suicidal Ideation000
SecondaryMean Change From Baseline in Positive and Negative Symptom Scale (PANSS) Total Score

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome). Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.

Time frame:
Baseline to Day 6, 11 and Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Positive and Negative Symptom Scale (PANSS) Total Score
Units on a scaleCohort 1 - Brexpiprazole 4mgCohort 2 - Brexpiprazole 1mgCohort 3 - Brexpiprazole 4mg
Day 6-4.0 ± 7.40.3 ± 4.0-2.0 ± 3.9
Day 11-1.5 ± 5.26.0 ± 11.1-4.0 ± 10.5
Last Visit-1.5 ± 5.26.0 ± 11.1-3.0 ± 8.7
SecondaryMean Change From Baseline in PANNS Positive Subscale Score

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.

Time frame:
Baseline to Day 6, 11 and Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANNS Positive Subscale Score
Units on a scaleCohort 1 - Brexpiprazole 4mgCohort 2- Brexpiprazole 1mgCohort 3 Brexpiprazole 4mg
Day 6-0.8 ± 1.00.0 ± 2.0-0.8 ± 3.9
Day 110.5 ± 1.00.5 ± 6.1-2.7 ± 7.5
Last Visit0.5 ± 1.00.5 ± 6.1-2.0 ± 6.3
SecondaryMean Change From Baseline in PANSS Negative Subscale Score

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.

Time frame:
Baseline to Day 6, 11 and Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANSS Negative Subscale Score
Units on a scaleCohort 1 - Brexpiprazole 4mgCohort 2- Brexpiprazole 1mgCohort 3 Brexpiprazole 4mg
Day 6-2.5 ± 4.41.0 ± 1.00.3 ± 1.0
Day 11-1.5 ± 2.40.5 ± 3.0-0.3 ± 3.2
Last Visit-1.5 ± 2.40.5 ± 3.0-0.3 ± 2.6
SecondaryMean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score

The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.

Time frame:
Baseline to Day 6, 11 and Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score
Units on a scaleCohort 1 - Brexpiprazole 4mgCohort 2- Brexpiprazole 1mgCohort 3 Brexpiprazole 4mg
Day 60.3 ± 0.50.0 ± 0.00.8 ± 1.0
Day 110.5 ± 1.00.0 ± 0.01.0 ± 1.0
Last Visit0.5 ± 1.00.0 ± 0.00.8 ± 1.0
SecondaryMean Change From Baseline in Clinical Global Impression-Improvement (CGI-I) Score

The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.

Time frame:
Baseline to Day 6, 11 and Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Clinical Global Impression-Improvement (CGI-I) Score
Units on a scaleCohort 1 - Brexpiprazole 4mgCohort 2- Brexpiprazole 1mgCohort 3 Brexpiprazole 4mg
Day 64.0 ± 0.04.0 ± 0.04.0 ± 0.0
Day 113.5 ± 1.03.8 ± 0.52.7 ± 1.2

Adverse events

Collected over Adverse events were reported once the informed consent was signed, throughout the 10-day treatment period until the safety follow-up via telephone 30 (+2) days post-last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 - Brexpiprazole 4 mg—0/4 (0%)4/4 (100%)
Cohort 2 - Brexpiprazole 1 mg—0/4 (0%)2/4 (50%)
Cohort 3 - Brexpiprazole 4 mg—0/4 (0%)3/4 (75%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventCohort 1 - Brexpiprazole 4 mgCohort 2 - Brexpiprazole 1 mgCohort 3 - Brexpiprazole 4 mg
Abdominal discomfortGastrointestinal disorders0/42/40/4
BlepharospasmEye disorders1/40/40/4
Abdominal painGastrointestinal disorders1/40/40/4
Dental carriesGastrointestinal disorders0/40/41/4
DyspepsiaGastrointestinal disorders1/40/41/4
FatigueGeneral disorders1/40/40/4
MalaiseGeneral disorders1/40/40/4
Musculoskeletal painMusculoskeletal and connective tissue disorders0/40/41/4
AkathisiaNervous system disorders1/40/41/4
SedationNervous system disorders1/40/40/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1 - Brexpiprazole 4 mgCohort 2 - Brexpiprazole 1 mgCohort 3 - Brexpiprazole 4 mgTotal
Mean38.3 ± 4.440.8 ± 11.945 ± 6.941.3 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 - Brexpiprazole 4 mgCohort 2 - Brexpiprazole 1 mgCohort 3 - Brexpiprazole 4 mgTotal
Female3115
Male1337
08

Study locations

1 site
  • Columbia University
    New York, New York 10032, United States
09

References and documents

Publications

  • Girgis RR, Forbes A, Abi-Dargham A, Slifstein M. A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology. 2020 Apr;45(5):786-792. doi: 10.1038/s41386-019-0590-6. Epub 2019 Dec 17. PubMed 31847007 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01854944
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Responsible party
Sponsor
First posted
May 16, 2013
Start date
Sep 2013
Primary completion
Jul 2014
Completion
Aug 2014
Results posted
Feb 4, 2016
Last update
Feb 4, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Schizophrenia→

Other studies from this sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Start the discussion